Skip to Content

Nivolumab plus Ipilimumab – A Potential New Standard-of-Care Treatment Option for Patients with MSI-H/dMMR Advanced Metastatic Colorectal Cancer

Thierry André presents the first results of the CheckMate 8HW study in this MEDtalk from ASCO GI 2024. The study is a s a randomized phase III study comparing nivolumab + ipilimumab with nivolumab or chemotherapy in patients with MSI-H/dMMR metastatic colorectal cancer, showing promising results for patients with dMMR/MSI-H advanced metastatic colorectal cancer.

Thierry André

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top